Information Provided By: 
Fly News Breaks for May 5, 2016
CVS
May 5, 2016 | 08:22 EDT
Leerink analyst David Larsen remains positive on CVS Health, saying its selling momentum continues into 2016. The analyst believes the company stands to benefit from the ongoing branded drug patent cliff and the high growth rate of specialty pharmaceuticals. Larsen also expects additional growth to come from the opening of new pharmacies and through acquisitions of independent pharmacies and smaller chains over the next several years. The analyst reiterates an Outperform and $110 price target on the shares.
News For CVS From the Last 2 Days
There are no results for your query CVS
